A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’

BACKGROUND AND PURPOSE: Nabiximols is a therapeutic option for patients with multiple sclerosis (MS) spasticity whose symptoms are poorly controlled by conventional oral first‐line medications. This study aimed to assess the relationship between changes in spasticity severity (measured on the 0–10 n...

Descripción completa

Detalles Bibliográficos
Autores principales: Patti, Francesco, Chisari, Clara Grazia, Fernández, Óscar, Sarroca, Jorge, Ferrer‐Picón, Elena, Hernández Vicente, Francisco, Vila Silván, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539865/
https://www.ncbi.nlm.nih.gov/pubmed/35590453
http://dx.doi.org/10.1111/ene.15412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539865/
https://www.ncbi.nlm.nih.gov/pubmed/35590453
http://dx.doi.org/10.1111/ene.15412

Ejemplares similares